tiprankstipranks
Trending News
More News >

Newron Pharma downgraded to Add from Buy at Baader Helvea

Baader Helvea downgraded Newron Pharma to Add from Buy with a price target of CHF 7.20, up from CHF 2.60. The analyst updated the model to account for evenamide’s recent success in the open-label trial in treatment-resistant schizophrenia. It cites valuation for the downgrade.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Disclaimer & DisclosureReport an Issue

1